Free Trial
NASDAQ:RVNC

Revance Therapeutics (RVNC) Stock Price, News & Analysis

Revance Therapeutics logo
$3.65 0.00 (0.00%)
As of 02/6/2025

About Revance Therapeutics Stock (NASDAQ:RVNC)

Key Stats

Today's Range
$3.65
$3.65
50-Day Range
$3.65
$3.65
52-Week Range
$2.41
$6.65
Volume
N/A
Average Volume
3.61 million shs
Market Capitalization
$381.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.45
Consensus Rating
Hold

Company Overview

Revance Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

RVNC MarketRank™: 

Revance Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 520th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Revance Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Revance Therapeutics has received no research coverage in the past 90 days.

  • Read more about Revance Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Revance Therapeutics are expected to grow in the coming year, from ($1.57) to ($1.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Revance Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Revance Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Revance Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for RVNC.
  • Dividend Yield

    Revance Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Revance Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for RVNC.
    • Insider Buying vs. Insider Selling

      In the past three months, Revance Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 5.10% of the stock of Revance Therapeutics is held by insiders.

    • Percentage Held by Institutions

      97.70% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Revance Therapeutics' insider trading history.
    Receive RVNC Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    RVNC Stock News Headlines

    Crown Laboratories Now Operates Under the Name Revance
    Trump wipes out trillions overnight…
    Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
    See More Headlines

    RVNC Stock Analysis - Frequently Asked Questions

    Revance Therapeutics' stock was trading at $3.04 at the start of the year. Since then, RVNC stock has increased by 20.1% and is now trading at $3.65.
    View the best growth stocks for 2025 here
    .

    Revance Therapeutics, Inc. (NASDAQ:RVNC) posted its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.12. The company's revenue was up 20.2% on a year-over-year basis.
    Read the conference call transcript
    .

    Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Revance Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Home Depot (HD).

    Company Calendar

    Last Earnings
    8/08/2024
    Today
    7/03/2025
    Next Earnings (Estimated)
    8/06/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:RVNC
    Employees
    500
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $8.45
    High Stock Price Target
    $20.00
    Low Stock Price Target
    $3.00
    Potential Upside/Downside
    +131.5%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.13
    Research Coverage
    8 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$323.99 million
    Pretax Margin
    -122.07%

    Debt

    Sales & Book Value

    Annual Sales
    $234.04 million
    Price / Cash Flow
    N/A
    Book Value
    ($1.73) per share
    Price / Book
    -2.11

    Miscellaneous

    Free Float
    99,066,000
    Market Cap
    $381.02 million
    Optionable
    Optionable
    Beta
    0.90

    Social Links

    The Best High-Yield Dividend Stocks for 2025 Cover

    Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

    Get This Free Report

    This page (NASDAQ:RVNC) was last updated on 7/3/2025 by MarketBeat.com Staff
    From Our Partners